Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 18, 2024

CNS Efficacy and Distant Metastases Outcomes of Osimertinib After Definitive Chemoradiotherapy in Patients With Unresectable Stage III EGFR-Mutated NSCLC

Annals of Oncology

 

Additional Info

Annals of Oncology
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Ann. Oncol 2024 Sep 11;[EPub Ahead of Print], S Lu, MJ Ahn, T Reungwetwattana, M Özgüroğlu, T Kato, JC Yang, M Huang, F Fujiki, T Inoue, LV Quang, V Sriuranpong, D Vicente, C Fuentes, AA Chaudhry, L Poole, E Armenteros Monterroso, Y Rukazenkov, T van der Gronde, SS Ramalingam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading